Enzymebiosystems (ENZB) 0.2500 $ENZB
EnzymeBioSystems Product Development Update
PR Newswire - Thu Aug 20, 12:30PM CDT
EnzymeBioSystems (OTCBB: ENZB - News) announces that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the Company.
Amooranin completes preclinical sample batch of methyl amooranin for reduction of breast tumors
M2 - Tue Jul 28, 5:54AM CDT
Enzymes company EnzymeBioSystems (OTC BB:ENZB) reported on Monday that it has completed a preclinical methyl amooranin batch in the prevention of breast cancer.
Amooranin Preclinical Sample Batch Completed
PR Newswire - Mon Jul 27, 5:41PM CDT
EnzymeBioSystems (OTC BB: ENZB - News) announces that a preclinical methyl amooranin batch has been completed. Amooranin is the Company's lead pharmaceutical product. EnzymeBioSystems plans to seek approval for the use of methyl amooranin in the prevention of breast cancer.
Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS
MCB).
EnzymeBioSystems: A Promotion Best Left Untouched
Hunter Straus - at Seeking Alpha - Mon Mar 16, 11:09PM CDT
EnzymeBioSystems Cleared for OTCQB Listing
ACCESSWIRE - Mon Mar 16, 12:12PM CDT
LAS VEGAS, NV / ACCESSWIRE / March 16, 2015 / EnzymeBioSystems (OTCQB: ENZB) announced that it received notice of approval from OTC Markets Group, Inc. ("OTC Markets"
that its stock will be listed on OTCQB Marketplace, effective March 16, 2015. ENZB submitted all the mandatory documents and has met all requirements for listing on the OTCQB Marketplace.
Market Maker Surveillance Report. NNBR, IDT, CTRV, ENZB, HTBX, ESCRP, Losing Stocks With Lowest Price Friction For Tuesday, March 10th 2015
M2 - Wed Mar 11, 4:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4960 companies with "abnormal" market making, 1371 companies with positive Friction Factors and 5291 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NN Inc (NASDAQ:NNBR), IDT Corp (NYSE:IDT), CARDILLO TRAVEL SYS (NASDAQ:CTRV), EnzymeBioSystems (OTC:ENZB), (NASDAQ:HTBX), (NASDAQ:ESCRP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
HTBX: 4.25 (+0.03), CTRV: 2.87 (-0.02), IDT: 14.00 (-0.28), ESCRP: 1.10 (+0.08), NNBR: 19.53 (-0.01)
EnzymeBioSystems' Amooranin preclinical sample batch to be completed by end of February 2015
M2 - Thu Feb 19, 5:13AM CST
Specialist enzymes company EnzymeBioSystems (OTCBB:ENZB) revealed on Wednesday that its preclinical methyl amooranin batch for the prevention of breast cancer nears completion.
Amooranin Preclinical Sample Batch Nears Completion
ACCESSWIRE - Wed Feb 11, 7:00AM CST
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.
Preclinical Xenograft Studies Show Positive Results For Amooranin
PR Newswire - Wed Dec 10, 12:45PM CST
EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.
EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid
PR Newswire - Mon Nov 17, 7:30AM CST
EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer. Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease. The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition). Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer. Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).
EnzymeBioSystems Announces Progress with an Enzyme Compound
PR Newswire - Tue Sep 23, 1:14PM CDT
EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces they have moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.
EnzymeBioSystems Product Development Update
PR Newswire - Thu Aug 20, 12:30PM CDT
EnzymeBioSystems (OTCBB: ENZB - News) announces that while it continues its early-stage research to obtain an Investigational New Drug Application for methyl amooranin, a product the prevention of breast cancer, management is pursuing other opportunities for the Company.
Amooranin completes preclinical sample batch of methyl amooranin for reduction of breast tumors
M2 - Tue Jul 28, 5:54AM CDT
Enzymes company EnzymeBioSystems (OTC BB:ENZB) reported on Monday that it has completed a preclinical methyl amooranin batch in the prevention of breast cancer.
Amooranin Preclinical Sample Batch Completed
PR Newswire - Mon Jul 27, 5:41PM CDT
EnzymeBioSystems (OTC BB: ENZB - News) announces that a preclinical methyl amooranin batch has been completed. Amooranin is the Company's lead pharmaceutical product. EnzymeBioSystems plans to seek approval for the use of methyl amooranin in the prevention of breast cancer.
Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS
MCB). EnzymeBioSystems: A Promotion Best Left Untouched
Hunter Straus - at Seeking Alpha - Mon Mar 16, 11:09PM CDT
EnzymeBioSystems Cleared for OTCQB Listing
ACCESSWIRE - Mon Mar 16, 12:12PM CDT
LAS VEGAS, NV / ACCESSWIRE / March 16, 2015 / EnzymeBioSystems (OTCQB: ENZB) announced that it received notice of approval from OTC Markets Group, Inc. ("OTC Markets"
that its stock will be listed on OTCQB Marketplace, effective March 16, 2015. ENZB submitted all the mandatory documents and has met all requirements for listing on the OTCQB Marketplace. Market Maker Surveillance Report. NNBR, IDT, CTRV, ENZB, HTBX, ESCRP, Losing Stocks With Lowest Price Friction For Tuesday, March 10th 2015
M2 - Wed Mar 11, 4:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4960 companies with "abnormal" market making, 1371 companies with positive Friction Factors and 5291 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NN Inc (NASDAQ:NNBR), IDT Corp (NYSE:IDT), CARDILLO TRAVEL SYS (NASDAQ:CTRV), EnzymeBioSystems (OTC:ENZB), (NASDAQ:HTBX), (NASDAQ:ESCRP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
HTBX: 4.25 (+0.03), CTRV: 2.87 (-0.02), IDT: 14.00 (-0.28), ESCRP: 1.10 (+0.08), NNBR: 19.53 (-0.01)
EnzymeBioSystems' Amooranin preclinical sample batch to be completed by end of February 2015
M2 - Thu Feb 19, 5:13AM CST
Specialist enzymes company EnzymeBioSystems (OTCBB:ENZB) revealed on Wednesday that its preclinical methyl amooranin batch for the prevention of breast cancer nears completion.
Amooranin Preclinical Sample Batch Nears Completion
ACCESSWIRE - Wed Feb 11, 7:00AM CST
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.
Preclinical Xenograft Studies Show Positive Results For Amooranin
PR Newswire - Wed Dec 10, 12:45PM CST
EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.
EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid
PR Newswire - Mon Nov 17, 7:30AM CST
EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer. Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease. The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition). Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer. Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).
EnzymeBioSystems Announces Progress with an Enzyme Compound
PR Newswire - Tue Sep 23, 1:14PM CDT
EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces they have moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.
